Here’s what you should know.
1. If Takeda acquires Shire, it would be the largest acquisition in Takeda’s history.
2. However, investors believe the acquisition would not provide enough of a boost to Takeda’s portfolio or pipeline.
3. Mizuho Securities analyst Hiroshi Tanaka said on the deal, “The impression left by the news is that the acquisition would be an overreach.”
4. Takeda acknowledged the rumors saying the company was merely considering the acquisition and had not yet submitted a bid.
More articles on supply chain:
7 things for ASC leaders to know for Thursday — March 29, 2018
Edmonds Orthopedic Center surgeons join SwiftPath Program for outpatient THR, TKR
Takeda, Protagonist Therapeutics & more — 5 GI company key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.